Pfizer Inc. (NYSE:PFE) stock price target increased to $36.00, issued a research note today by Jefferies Group
- Updated: October 12, 2016
Yesterday Pfizer Inc. (NYSE:PFE) traded -1.04% lower at $33.07. The company’s 50-day moving average is $34.14 and its 200-day moving average is $34.26. The last closing price is down -4.48% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 2,474,112 shares of the stock traded hands, down from an average trading volume of 18,868,500
In a report released on 10/13/2016 Jefferies Group increased the stock price target of Pfizer Inc. (NYSE:PFE) to $36.00 indicating a possible upside of 0.09%.
Previously on 5/12/2016, Berenberg Bank reported on Pfizer Inc. (NYSE:PFE) increased the target price from $0.00 to $38.00. At the time, this indicated a possible upside of 0.15%.
See Chart Below
Pfizer Inc. has a 52 week low of $28.25 and a 52 week high of $37.39 with a P/E ratio of 29.01 The company’s market cap is currently $0.
In addition to Jefferies Group reporting its stock price target, a total of 20 brokers have issued a research note on the company. The average stock price target is $38.58 with 4 brokers rating the stock a strong buy, 10 brokers rating the stock a buy, 7 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.
General Information About Pfizer Inc. (NYSE:PFE)
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products. Its biotechnology products include BeneFIX, ReFacto and Xyntha. The Company's contract manufacturing business, Pfizer CentreOne, consists of its contract manufacturing and active pharmaceutical ingredient sales operation, including manufacturing and supply agreements with Zoetis Inc., and Hospira's One-2-One sterile injectables contract manufacturing operation. Its research focuses on six areas, which include immunology and inflammation, cardiovascular and metabolic diseases, oncology, vaccines, neuroscience and pain, and rare diseases. The Company's subsidiaries include Hospira, Inc. and Medivation, Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.